TOU:TSX
Tourmaline Oil Corp.
Data as of 2026-03-11 - not real-time
CA$62.77
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Tourmaline Oil is trading at C$62.77, just above the computed support of C$60.58 and below the resistance of C$67.65. The price sits marginally under the 20‑day SMA (C$62.89) but remains above the 50‑day (C$61.80) and 200‑day (C$61.65) averages, signalling a longer‑term bullish bias. Momentum indicators are mixed – RSI sits at 49.6, essentially neutral, while the MACD histogram is slightly negative, hinting at short‑term pressure despite an overall bullish trend and increasing volume. Fundamentally, the company posted strong revenue growth of 19% and a record Q4 production of 659,204 boepd, with January 2026 averaging over 685,000 boepd. A corporate‑record 2P reserve addition of 829 million boe and a $765 million asset sale bolster the balance sheet, yet leverage remains high with a debt‑to‑equity ratio of 12.25 and a dividend payout ratio of 294%, raising concerns about dividend sustainability. Forward earnings are projected to surge – trailing EPS is C$0.68 versus a forward EPS of C$4.83, compressing the forward P/E to about 13 versus a trailing P/E of 92, well above the industry average of 20. Analyst consensus is a “Buy” with a median target of C$72, implying roughly 14% upside, while the DCF model suggests a fair value near C$180, indicating significant long‑term upside potential if cash flow improves and leverage is reduced.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Price near technical support with bullish longer‑term moving averages
- Mixed MACD signal indicating possible short‑term pullback
- Upcoming ex‑dividend date and high payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward P/E compression to ~13 and strong EPS growth outlook
- Reserve addition of 829 million boe and cost reductions to $4.66/boe
- Analyst median target of C$72 providing ~14% upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value estimate around C$180 indicating substantial long‑term upside
- Low beta (0.5) and increasing production scale
- High leverage and unsustainable dividend payout requiring balance‑sheet deleveraging
Key Metrics & Analysis
Financial Health
Revenue Growth18.80%
Profit Margin5.72%
P/E Ratio92.3
ROE1.70%
ROA0.22%
Debt/Equity12.25
P/B Ratio1.6
Op. Cash FlowCA$3.4B
Free Cash FlowCA$-1681757952
Industry P/E20.3
Technical Analysis
TrendBullish
RSI49.6
SupportCA$60.58
ResistanceCA$67.65
MA 20CA$62.89
MA 50CA$61.80
MA 200CA$61.65
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair ValueCA$179.92
Target PriceCA$70.43
Upside/Downside12.21%
GradeUndervalued
TypeGrowth
Dividend Yield3.14%
Risk Assessment
Beta0.51
Volatility31.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.